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Innovations in vital signs measurement for
the detection of hypertension and shock in
pregnancy
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Belagavi, India. 26-27 March 2018
Abstract
Approximately 820 women die in pregnancy and childbirth every day worldwide, with 99% of these occurring in
low-resource settings. The most common causes of maternal mortality are haemorrhage, sepsis and hypertensive
disorders. There are established, effective solutions to these complications, however challenges remain in
identifying who is at greatest risk and ensuring that interventions are delivered early when they have the greatest
potential to benefit. Measuring vital signs is the first step in identifying women at risk. Overstretched or poorly
trained staff and inadequate access to accurate, reliable equipment to measure vital signs can potentially result in
delayed treatment initiation. Early warning systems may help alert users to identify patients at risk, especially where
novel technologies can improve usability by automating calculations and alerting users to abnormalities. This may
be of greatest benefit in under-resourced settings where task-sharing is common and early identification of
complications can allow for prioritisation of life-saving interventions. This paper highlights the challenges of
accurate vital sign measurement in pregnancy and identifies innovations which may improve detection of
pregnancy complications.
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Background
Haemorrhage is the leading cause of maternal mortality
worldwide (27.1%), followed by hypertensive disorders
(14.0%) and sepsis (10.7%) [1]. The individual treatment
components of antibiotics for sepsis, uterotonics and
blood transfusion for haemorrhage and magnesium sul-
fate for eclampsia have proven efficacy several decades
ago and are readily available in most settings [2]. Despite
this and recent efforts to reduce maternal mortality, in
2015, an estimated 820 women died every day as a result
of pregnancy and childbirth, 99% of which occurred in
low-resource settings [3].
Timely identification and treatment of pregnancy com-
plications is critical in order to save lives. Yet over-
stretched and inadequately trained staff and insufficient
access to reliable, accurate equipment can cause delays
in diagnosis and management of maternal complications,
thus contributing to maternal mortality and serious mor-
bidity [4]. The need for early recognition of abnormal
vital signs has been highlighted by the Confidential En-
quiries report. It has been identified that failure to
recognize and act on deteriorating vital signs in a timely
manner contributed to avoidable maternal deaths [5, 6].
Strategies to improve timely recognition of women who
require intervention to treat life-threatening pregnancy
complications may prevent morbidity and mortality. Es-
pecially in low-resource settings, where the burden of
disease from preventable conditions is so great and
accessing appropriate care is critical [4].
This commentary aims to highlight the challenges of
accurate vital sign measurement in pregnancy and de-
scribe recent innovations that may aid in earlier* Correspondence: nicola.vousden@kcl.ac.uk
Department of Women and Children’s Health, School of Life Course
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detection of complications and reduction of maternal
morbidity worldwide.
Detecting hypertension in pregnancy
Approximately, 10% of women experience hypertension
(> 140/90) during pregnancy [7]. Pre-eclampsia, new
hypertension with proteinuria or end-organ damage after
20 weeks of gestation [8] can manifest in the absence of
physical symptoms. Despite promising advances
(biomarkers, Doppler velocimetry and prediction models
[9]), there are currently no specific screening tests for
pre-eclampsia that have sufficient clinical and cost effect-
iveness to be uniformly adopted into clinical practice [10].
Blood pressure (BP) monitoring therefore remains the
most important and frequent screening test undertaken
during the antenatal period [11]. It is essential for
detecting and monitoring pre-eclampsia, enabling antihy-
pertensive and prophylactic anticonvulsant therapy and
appropriate transfer to higher care facilities for timed de-
livery. Indeed, failure to accurately measure, understand
and act on abnormal blood pressures in pregnancy results
in increased mortality and morbidity [12, 13].
There are several methods of blood pressure measure-
ment. Auscultation using a sphygmomanometer is a
relatively low-cost technique, but this requires a skilled
observer to accurately auscultate to the nearest 2 mmHg.
Previous studies have demonstrated that this infre-
quently occurs and that 78% of readings obtained by cli-
nicians in antenatal clinic end in a zero [14]. This
observer preference is a source of error in measuring
vital signs. Additionally, mercury devices are no longer
in clinical use in Europe due to concerns over the tox-
icity of mercury. Aneroid devices replace the mercury
column but still rely on accurate auscultation. They also
require more regular maintenance and calibration than
mercury, with studies demonstrating that 53% of aneroid
devices in the UK General Practice read an error of
more than +/− 3 mmHg, which is significantly more
than mercury or automated devices (8%) [15].
Automated BP devices use oscillometry to avoid the
necessity of auscultation by a skilled user. It is recom-
mended by the British Society of Hypertension and the
European Society of Hypertension that they are inde-
pendently validated to ensure accuracy [16]. However,
there are hundreds of commercially available automated
devices and only a few have been successfully validated.
Even fewer have been validated as accurate in the preg-
nant population [17]. Automated devices are prone to
underestimate BP in women with pre-eclampsia, and
this can result in missing a diagnosis of hypertension in
women at high-risk of pregnancy complications [18].
Self-monitoring in pregnancy is increasing in popular-
ity, and evidence suggests that it is acceptable to women
[9]. However, accuracy is dependent on use of a device
validated for home use, of which only five have
undergone testing using accepted protocols [10]. Evi-
dence supporting the safety and effectiveness of
self-monitoring in improving clinical outcomes is scarce
and therefore current guidance on frequency of monitor-
ing is lacking [10]. Wearable technologies have become
a recent priority in several global heath funding calls.
Wireless vital sign measurements may be of benefit dur-
ing acute hospital admissions and labour, but current
evidence to support their use is limited [19].
Detecting shock in pregnancy
Given that the majority of maternal deaths are a result
of haemorrhage or sepsis it is crucial to measure vital
signs in order to allow for early detection of shock.
Shock is defined as inadequate tissue perfusion and is
classically defined by the presence of tachycardia,
hypotension and eventually poor end-organ perfusion
[20]. Detecting shock in pregnancy can be complicated
by the physiological changes of pregnancy including in-
creased circulatory blood volume. This means that a
large volume of blood can be lost before clinical decom-
pensation [20]. Therefore, physiological parameters of
shock used outside of pregnancy may not be directly
comparable during pregnancy.
Sepsis is defined as life-threatening organ dysfunction
caused by a dysregulated host response to infection [21].
However, international guidelines and criteria of sepsis
are not specific for pregnancy and some vital sign
thresholds may not be appropriate. For example, women
experience a physiological baseline tachycardia in preg-
nancy that may render the threshold of heart rate (HR)
> 90 bpm too low. This may be especially problematic in
low-resource countries with high rates of anaemia in the
pregnant population. In 2017, the WHO defined mater-
nal sepsis as a life-threatening condition defined by
organ dysfunction resulting in infection during preg-
nancy, childbirth, post-abortion or postpartum period
[22]. However, this definition does not set thresholds for
vital signs that should alert health care providers (HCPs)
that the mother is at risk. The UK Sepsis Trust, in col-
laboration with the National Institute for Health and
Care Excellence (NICE), have recently released guide-
lines and a maternal sepsis tool to improve detection of
sepsis in pregnancy. These list ‘amber’ and ‘red’ flag cri-
teria specific to maternal sepsis that should trigger initi-
ation of management such as intravenous fluids and
blood cultures [23].
Alongside the measurement of HR and BP to detect
shock secondary to haemorrhage or sepsis, Shock Index
(SI), is a promising marker of compromise in pregnancy.
SI is the ratio of HR to systolic BP. In the non-pregnant
population, it was proposed as an earlier marker of
blood loss in patients with gastrointestinal haemorrhage
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over 60 years ago [24]. There have been a number of
studies outside of pregnancy that have demonstrated
that an elevated SI is associated with adverse outcomes
or mortality secondary to haemorrhage [25, 26] or sepsis
[27]. The potential for Shock Index as a predictive
marker in pregnancy was first explored in women with
early pregnancy complications [28, 29]. More recently, a
number of small case-control studies have explored the
use of SI in obstetric haemorrhage [30, 31]. SI has
been shown to be significantly higher in those with
post-partum haemorrhage (PPH), those receiving trans-
fusion and those requiring hysterectomy compared to
controls with a normal blood loss at delivery [32]. Add-
itionally, SI is significantly higher in those that require
massive blood transfusion following PPH compared to
those requiring less than 10 units of blood [31].
Shock Index may therefore be a useful measure of
early compromise following delivery. However, it is vital
that the distribution of values in the normal population
are understood so that thresholds of abnormality that
should alert HCPs can be identified. A retrospective co-
hort study of 192 low-risk women demonstrated that the
mean SI for all pregnancy lengths beyond 12 weeks was
0.79 (+/− 0.13) [33]. This reflected a trend towards lower
values in the first trimester, slight increases in the sec-
ond trimester and decreasing values from 37 weeks on-
wards with a normal distribution throughout the
population. In the first hour after birth, it has been
shown that women with a normal blood loss (< 500 ml)
have a median SI of 0.66 (0.52–0.89) [34]. The upper
limit of 0.89 supports the growing body of literature sug-
gesting that a SI > 0.9 is associated with increased risk of
adverse outcomes in pregnancy. For example, a study of
233 women with major PPH ≥ 1500 ml in a UK tertiary
setting that a SI ≥ 0.9 had a 100% sensitivity (95% CI
73.5–100) and 43% specificity (95% CI 36.8–50.3) for
predicting intensive care unit admission. In comparison,
a SI ≥ 1.7 indicated urgent attention was required, with
a 25% sensitivity (95% CI 5.5–57.2) and 98% specificity
(CI 94.8–99.3) for predicting ICU admission [35]. This
was also reflected in the largest study to date, where in
958 women with PPH (≥ 750 ml in Egypt and Nigeria or
≥ 500 ml in Zambia or Zimbabwe) SI was the most con-
sistent predictor of adverse maternal outcomes including
maternal death [36].
Early detection of compromise in pregnancy
Early recognition of abnormal vital signs, including heart
rate (HR), blood pressure (BP), respiratory rate, oxygen
saturation and temperature can allow for timely identifi-
cation of clinical deterioration. In high-income settings,
it is common for vital signs to be recorded on a
paper-based Early Warning System (EWS), a tool to
allow for tracking of vital signs according to thresholds
of physiological parameters. When abnormal vital signs
are identified and plotted, the colour of the paper (nor-
mally yellow or red) highlights the severity of deviation
from normal, and therefore the need to escalate care
[37]. Since the Confidential Enquiries report recommen-
dation in 2003–2005, EWS have been incorporated into
maternity care across the UK [38]. Several studies demon-
strate that EWS predict morbidity [39, 40] yet there is a
lack of evidence demonstrating the clinical effectiveness.
It has been reported that EWS improves communication
between HCPs and enabled legitimacy for escalation of
care, despite significant cultural boundaries and hierarch-
ies that delay appropriate care [41]. However, it is recog-
nised that effectiveness of EWS is dependent on accurate
measurement of vital signs, accurate documentation and
effective communication [37]. Staffing pressures are per-
ceived as the greatest barriers to their use [38], and this is
likely to be of even greater significance in overwhelmed,
low-resource environments.
Novel technologies that incorporate EWS calculations
and alert HCPs to abnormalities may reduce errors in
paper-based recording and delays in communication, po-
tentially saving maternal lives. For example, VitalPAC is
a software system that automatically analyses and alerts
HCPs to changes in vital signs. Studies have demon-
strated that its use improves accuracy of documentation
[42, 43] and non-maternity clinical outcomes [44] but
the observational, uncontrolled design of these studies
limits interpretation of findings. Additionally, it requires
transcription of vital signs into the system which may be
associated with error and requires technologies that are
not widely available in low-resource settings.
A simpler solution is the Microlife CRADLE Vital Sign
Alert (VSA), a semi-automated hand-held upper arm de-
vice that measures HR, BP and automatically calculates SI.
It has been validated as accurate outside of pregnancy [22]
as well as in pregnancy, including women with hyperten-
sion [45] or hypotension [46]. It has been developed spe-
cifically for use in low-resource settings, with low power
requirements and a built-in, rechargeable battery that can
be charged with a micro-USB (the same as most inter-
national phone chargers). Results are shown on a digital
display as well as an EWS traffic light. The lights are trig-
gered by both hypertension and SI. A BP of ≥140 or ≥90
will trigger a yellow light with an arrow pointing up to in-
dicate mild hypertension and ≥160 or ≥ 90 will trigger a
red light with an arrow pointing up to indicate severe
hypertension. Prospective evaluation of these thresholds
in 1547 women with pre-eclampsia in South Africa dem-
onstrated that a red or yellow light on admission was asso-
ciated with significantly increased rates of kidney injury
(OR 1.74, CI 1.31–2.33) and the need for magnesium sul-
fate (OR 3.40, CI 2.24–5.18) and high dependency admis-
sion (OR 1.50, CI 1.18–1.91) [47].
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Additionally, a SI of < 0.9 will trigger a green light to
reassure that the vital signs are within the parameters of
normal. A SI of ≥0.9–1.69 will trigger a yellow light with
an arrow pointing down to alert the HCP to the poten-
tial need for action. A red light with a down arrow is
triggered by a SI ≥1.7, highlighting to any cadre of HCP,
even those without formal clinical training, that there is
a high risk of adverse outcome and immediate action is
required. Prospective validation of these thresholds in
sepsis and haemorrhage in the pregnant population has
recently completed with initial analysis showing promis-
ing results. Qualitative data (155 interviews with HCPs
and 41 with pregnant women and their families) have in-
dicated that HCPs found the CRADLE VSA easy to use
and that the traffic light EWS improved confidence in
decision-making and professionalism [48]. Women and
their families reported that the traffic light EWS im-
proved understanding of the importance of vital signs in
pregnancy [48]. Results of a stepped-wedge randomized
controlled trial introducing this device into routine ma-
ternity care in 10 low-resource settings with the aim of
reducing maternal mortality and morbidity are eagerly
anticipated (ISRCTN41244132).
Conclusion
In conclusion, despite dramatic progress in the last dec-
ade, addressing maternal mortality remains appropriately
high on the international agenda. Vital signs measure-
ment remains a vital first step in detecting pregnancy
abnormalities in order to initiate timely treatments that
can save lives. Inadequate access to accurate, reliable
equipment in combination with strain on trained health
care providers can lead to delay in recognition of preg-
nancy complications. EWS may be of benefit in alerting
HCPs to abnormal results. Novel technologies such as
traffic light alerts may present a user-friendly solution.
This may be of greatest benefit in under-resourced set-
tings where task-sharing with HCPs with less formal
training is common [49].
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